Compare YQ & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YQ | LGVN |
|---|---|---|
| Founded | 2012 | 2014 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Medicinal Chemicals and Botanical Products |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.2M | 25.9M |
| IPO Year | 2020 | 2021 |
| Metric | YQ | LGVN |
|---|---|---|
| Price | $2.30 | $0.83 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 6.5K | ★ 465.2K |
| Earning Date | 06-09-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.76 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $709,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $10.81 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.68 | $0.48 |
| 52 Week High | $6.45 | $1.23 |
| Indicator | YQ | LGVN |
|---|---|---|
| Relative Strength Index (RSI) | 59.25 | 62.15 |
| Support Level | $1.84 | $0.62 |
| Resistance Level | $2.63 | $0.87 |
| Average True Range (ATR) | 0.23 | 0.07 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 81.11 | 73.23 |
17 Education & Technology Group Inc is engaged in providing education and education technology services in the People's Republic of China (PRC) with a focus on the Teaching and Learning SaaS offerings. It offers smart, in-school, teaching and learning SaaS offerings assist students, teachers, schoolmasters and educational authorities across China. It also offer other educational products and services that complement students' in-school learning. Geographically group operates in China.
Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.